Frontiers in medicine · 2026
Association between risk-weighted apolipoprotein B and prevalent kidney stones: a retrospective case-control study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xiaogang, Shen Xin, Liu Mengwei, Liu Yi, Zhang Qiankun, Xu Hao, Zhang Xiansheng
Аннотация
OBJECTIVE: To investigate the association between risk-weighted apolipoprotein B (RW-apoB) levels and prevalent kidney stones.
METHODS: This retrospective case-control study included 761 subjects, comprising a non-stone group (n = 522) and an incident kidney stone group confirmed strictly by non-contrast computed tomography (NCCT) (n = 239). Multivariable logistic regression models were utilized to evaluate the association between RW-apoB and prevalent kidney stones. To address unmeasured confounding from potential lipid-lowering therapies, a sensitivity analysis was conducted by excluding individuals with comorbid hypertension and diabetes. Additionally, subgroup analyses were performed to assess the stability of this association across different clinical characteristics.
RESULTS: Baseline analysis revealed that RW-apoB levels in the kidney stone group were significantly higher than those in the non-stone group (95.89 ± 28.80 vs. 88.52 ± 24.42, p < 0.001). Multivariable logistic regression analysis indicated that continuously elevated RW-apoB levels were significantly associated with prevalent kidney stones (OR = 1.01, 95% CI: 1.00-1.02). In the strict sensitivity analysis excluding hypertensive and diabetic patients, this positive association remained consistent (OR = 1.01, 95% CI: 1.00-1.03). Furthermore, stratified analysis demonstrated that this positive association between RW-apoB and kidney stones remained relatively consistent across subgroups defined by age, gender, and metabolic comorbidities.
CONCLUSIONS: Higher RW-apoB was associated with prevalent kidney-stone status after adjustment for measured clinical covariates.
METHODS: This retrospective case-control study included 761 subjects, comprising a non-stone group (n = 522) and an incident kidney stone group confirmed strictly by non-contrast computed tomography (NCCT) (n = 239). Multivariable logistic regression models were utilized to evaluate the association between RW-apoB and prevalent kidney stones. To address unmeasured confounding from potential lipid-lowering therapies, a sensitivity analysis was conducted by excluding individuals with comorbid hypertension and diabetes. Additionally, subgroup analyses were performed to assess the stability of this association across different clinical characteristics.
RESULTS: Baseline analysis revealed that RW-apoB levels in the kidney stone group were significantly higher than those in the non-stone group (95.89 ± 28.80 vs. 88.52 ± 24.42, p < 0.001). Multivariable logistic regression analysis indicated that continuously elevated RW-apoB levels were significantly associated with prevalent kidney stones (OR = 1.01, 95% CI: 1.00-1.02). In the strict sensitivity analysis excluding hypertensive and diabetic patients, this positive association remained consistent (OR = 1.01, 95% CI: 1.00-1.03). Furthermore, stratified analysis demonstrated that this positive association between RW-apoB and kidney stones remained relatively consistent across subgroups defined by age, gender, and metabolic comorbidities.
CONCLUSIONS: Higher RW-apoB was associated with prevalent kidney-stone status after adjustment for measured clinical covariates.